
Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discu...
12 Aug 202422min

Discussing PsA: Guselkumab and analysis of genetic markers
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receivin...
12 Aug 202425min

Author Interview: Dr Adam Goldman, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher an...
8 Aug 202421min

Author Interview: Professor Daniel Blockmans, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his rec...
25 Jul 202426min

Discussing RA: July 2024
Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In...
18 Jul 202423min

Discussing RA: June 2024
Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In t...
27 Jun 202425min

EULAR 2024 Review Podcast
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will sh...
19 Jun 202436min

EULAR 2024 Highlights: Day 4
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).
15 Jun 20242min



















